<DOC>
	<DOCNO>NCT01494805</DOCNO>
	<brief_summary>The study involve approximately 40 subject age 55 exudative age-related macular degeneration ( wet AMD ) . Patients randomize receive one two dose rAAV.sFlt-1 assign control group .</brief_summary>
	<brief_title>Safety Efficacy Study rAAV.sFlt-1 Patients With Exudative Age-Related Macular Degeneration</brief_title>
	<detailed_description>A new treatment exudative age-related macular degeneration ( wet AMD ) investigate . The purpose Phase I/II clinical research study examine baseline safety efficacy experimental study drug treat complication disease lead vision loss . The name study drug rAAV.sFlt-1 . This experimental study use non-pathogenic virus express therapeutic protein within eye . The therapeutic diminishes growth abnormal blood vessel retina . The duration effect think long-term ( year ) follow single administration . The clinical research study look baseline safety efficacy single injection rAAV.sFlt-1 inject directly eye . Approximately forty ( 40 ) subject participate Australia . The primary endpoint study one month , extend follow 3 year .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Retinal Degeneration</mesh_term>
	<mesh_term>Retinal Neovascularization</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Age great equal 55 year ; Subfoveal CNV secondary AMD best correct visual acuity 3/60 6/9 6/60 good eye ; Fluorescein angiogram study eye must show evidence leak subfoveal choroidal neovascular lesion , CNV currently active management antiVEGF therapy ; Must candidate antiVEGF intravitreal injection ; No previous retinal treatment photodynamic therapy laser ; Able provide inform consent ; Able comply protocol requirement , include followup visit . Liver enzymes &gt; 2 X upper limit normal ; Any prior treatment AMD study / control eye , exclude antiVEGF injection ; Extensive subfoveal scarring , extensive geographic atrophy , thick subretinal blood study eye determine investigator ; Significant retinal disease subfoveal CNV AMD ;</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Age-related Macular Degeneration</keyword>
	<keyword>AAV</keyword>
	<keyword>AMD</keyword>
	<keyword>Wet AMD</keyword>
	<keyword>Neovascular AMD</keyword>
	<keyword>Gene Therapy</keyword>
	<keyword>Ocular</keyword>
	<keyword>Ocular Gene Therapy</keyword>
	<keyword>Eye disease</keyword>
	<keyword>Macular Degeneration</keyword>
	<keyword>Retinal Degeneration</keyword>
	<keyword>Retinal Neovascularization</keyword>
	<keyword>Wet Macular Degeneration</keyword>
	<keyword>Retinal Diseases</keyword>
</DOC>